{
  "meta": {
    "title": "Copd",
    "url": "https://brainandscalpel.vercel.app/copd-ce6680ac.html",
    "scrapedAt": "2025-11-30T08:49:01.277Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">Intermittent respiratory symptoms</span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">Presence of airflow obstruction </span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">Destruction of lung alveoli may be present</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">All of the above</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is INCORRECT about chronic obstructive pulmonary disease?</span></p>",
      "unique_key": "DT1295680",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295680,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Correct Answer</strong>: <strong>Intermittent respiratory symptoms:</strong> This is incorrect regarding COPD; patients typically experience <strong>persistent</strong> respiratory symptoms rather than intermittent ones.</li>\r\n<li><strong>COPD Definition</strong>:\r\n<ul>\r\n<li>Characterized by <strong>persistent respiratory symptoms</strong> (e.g., chronic cough, sputum production).</li>\r\n<li><strong>Airflow obstruction</strong> that is not fully reversible.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Destruction of Lung Alveoli</strong>:\r\n<ul>\r\n<li>Commonly occurs, particularly in emphysema, leading to decreased surface area for gas exchange.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Why Not Other Options:</strong></p>\r\n<ul>\r\n<li><strong> Presence of airflow obstruction</strong>: Correct; airflow obstruction is a hallmark of COPD.</li>\r\n<li><strong> Destruction of lung alveoli may be present</strong>: Correct; alveolar destruction is characteristic of COPD.</li>\r\n<li><strong> All of the above</strong>: Incorrect since option A is the only incorrect statement.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li>COPD is defined by <strong>persistent</strong> respiratory symptoms and airflow obstruction.</li>\r\n<li>Understanding the key characteristics of COPD aids in its diagnosis and management.</li>\r\n</ul>\r\n\r\n",
      "correct_choice_id": 1,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">Emphysema</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">Small airway disease</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">Bronchiectasis</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">Chronic Bronchitis</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">COPD includes all of the following except?</span></p>",
      "unique_key": "DT1295683",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295683,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Correct Answer</strong>: <strong>Bronchiectasis</strong> - This condition is <strong>not</strong> classified under COPD.</li>\r\n</ul>\r\n<p><strong>Key Features of COPD:</strong></p>\r\n<ul>\r\n<li><strong>Included Conditions</strong>:\r\n<ul>\r\n<li><strong>Emphysema</strong>: Involves destruction of lung alveoli, leading to reduced gas exchange.</li>\r\n<li><strong>Chronic Bronchitis</strong>: Characterized by chronic productive cough due to inflammation and mucus production.</li>\r\n<li><strong>Small Airway Disease</strong>: Involves narrowing of small bronchioles, contributing to airflow limitation.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Why Not Other Options:</strong></p>\r\n<ul>\r\n<li><strong> Emphysema</strong>: Correctly included in COPD due to alveolar destruction.</li>\r\n<li><strong> Small Airway Disease</strong>: Part of the COPD spectrum as it leads to airflow obstruction.</li>\r\n<li><strong> Chronic Bronchitis</strong>: A key component of COPD due to chronic inflammation and cough.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li>COPD encompasses <strong>emphysema</strong>, <strong>chronic bronchitis</strong>, and <strong>small airway disease</strong>.</li>\r\n<li><strong>Bronchiectasis</strong> is a separate respiratory condition characterized by abnormal dilation of bronchi, not included in the COPD classification.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 13,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\">Bronchial asthma</span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\">COPD</span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\">Bronchiectasis</span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\">All of the above </span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">GOLD criteria is used for airway obstruction in which of the following disease?</span></p>",
      "unique_key": "DT1295686",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295686,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Correct Answer</strong>: <strong>COPD</strong> The GOLD criteria is specifically used to assess airway obstruction severity in this disease.</li>\r\n</ul>\r\n<p><strong>Key Features of GOLD Criteria:</strong></p>\r\n<ul>\r\n<li><strong>Purpose</strong>: Evaluates the severity of airflow obstruction in <strong>COPD</strong>.</li>\r\n<li><strong>Mandatory Diagnostic Criterion</strong>:\r\n<ul>\r\n<li><strong>FEV1/FVC &lt; 0.70</strong> confirms airflow obstruction.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Classification</strong>:\r\n<ul>\r\n<li><strong>Mild COPD</strong>: FEV1 &gt; 80% of predicted.</li>\r\n<li><strong>Moderate COPD</strong>: FEV1 &lt; 80% of predicted.</li>\r\n<li><strong>Severe COPD</strong>: FEV1 &lt; 50% of predicted.</li>\r\n<li><strong>Very Severe COPD</strong>: FEV1 &lt; 30% of predicted.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Why Not Other Options:</strong></p>\r\n<ul>\r\n<li><strong> Bronchial Asthma</strong>: Not classified using GOLD; asthma has different guidelines.</li>\r\n<li><strong> Bronchiectasis</strong>: Also not included in the GOLD criteria for COPD assessment.</li>\r\n<li><strong> All of the Above</strong>: Incorrect as only COPD uses the GOLD criteria.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li>The <strong>GOLD criteria</strong> is crucial for diagnosing and staging <strong>COPD</strong> based on airflow obstruction.</li>\r\n<li>Understanding the impact of <strong>cigarette smoking</strong> is vital, as it contributes to various airway changes, including mucus gland enlargement and bronchial hyperreactivity.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 22,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">Pan lobular emphysema</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">Centrilobular emphysema</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">Para septal emphysema</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">All of the above</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Anti-trypsin deficiency is associated with development of which of the following type of Emphysema?</span></p>",
      "unique_key": "DT1295688",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295688,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Correct Answer</strong>: <strong>Pan lobular emphysema</strong> - This type is specifically associated with <strong>anti-trypsin deficiency</strong>.</li>\r\n</ul>\r\n<p><strong>Types of Emphysema:</strong></p>\r\n<ol>\r\n<li><strong>Centrilobular Emphysema</strong>:\r\n<ul>\r\n<li>Most common with <strong>cigarette smoking</strong>.</li>\r\n<li>Characterized by enlarged air spaces around respiratory bronchioles.</li>\r\n<li>Primarily affects <strong>upper lobes</strong> and <strong>superior segments of lower lobes</strong>.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Pan lobular Emphysema</strong>:\r\n<ul>\r\n<li><strong>Associated with &alpha;1-antitrypsin (&alpha;1AT) deficiency</strong>.</li>\r\n<li>Features <strong>uniformly enlarged air spaces</strong> throughout acinar units.</li>\r\n<li>Predominantly affects the <strong>lower lobes</strong>.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Para septal Emphysema</strong>:\r\n<ul>\r\n<li>Found along <strong>pleural margins</strong>, with sparing of central lung areas.</li>\r\n<li>Comprises <strong>10-15%</strong> of cases and often accompanies <strong>centrilobular emphysema</strong>.</li>\r\n</ul>\r\n</li>\r\n</ol>\r\n<p><strong>Why Not Other Options:</strong></p>\r\n<ul>\r\n<li><strong> Centrilobular Emphysema</strong>: Primarily linked to <strong>smoking</strong>, not &alpha;1AT deficiency.</li>\r\n<li><strong> Para septal Emphysema</strong>: Not specifically associated with &alpha;1AT deficiency; more common with airway inflammation.</li>\r\n<li><strong> All of the Above</strong>: Incorrect, as only <strong>pan lobular emphysema</strong> is related to anti-trypsin deficiency.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Pan lobular emphysema</strong> is directly linked to <strong>&alpha;1AT deficiency</strong>, affecting the lower lobes.</li>\r\n<li>Understanding the classifications of emphysema is crucial for appropriate diagnosis and management of <strong>COPD</strong>.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 31,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">Disproportionate and persistent reduction in FEV1</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">Hyperinflation</span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">Flattening of diaphragm </span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">Uniform ventilation perfusion matching </span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is not a feature of emphysema?</span></p>",
      "unique_key": "DT1295721",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295721,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Correct Answer</strong>: <strong>Uniform ventilation perfusion matching</strong>&nbsp;This is <strong>not</strong> a feature of emphysema.</li>\r\n</ul>\r\n<p><strong>Common Features of Emphysema:</strong></p>\r\n<ol>\r\n<li><strong>Disproportionate and Persistent Reduction in FEV1</strong>:\r\n<ul>\r\n<li>Significant decrease in <strong>FEV1</strong> relative to <strong>FVC</strong>, indicative of <strong>airflow obstruction</strong>.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Hyperinflation</strong>:\r\n<ul>\r\n<li>Resulting from <strong>air trapping</strong> due to airway obstruction.</li>\r\n<li>Manifested as <strong>increased residual volume</strong> and a higher ratio of <strong>Residual Volume (RV)</strong> to <strong>Total Lung Capacity (TLC)</strong>.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Flattening of Diaphragm</strong>:\r\n<ul>\r\n<li>Occurs due to <strong>hyperinflation</strong>, leading to decreased respiratory efficiency.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Nonuniform Ventilation and Ventilation-Perfusion (V/Q) Mismatch</strong>:\r\n<ul>\r\n<li>Emphysema typically exhibits <strong>nonuniform V/Q matching</strong> due to heterogeneous lung destruction.</li>\r\n</ul>\r\n</li>\r\n</ol>\r\n<p><strong>Why Not Other Options:</strong></p>\r\n<ul>\r\n<li><strong>A. Disproportionate and Persistent Reduction in FEV1</strong>: A hallmark feature of emphysema.</li>\r\n<li><strong>B. Hyperinflation</strong>: A common finding in emphysema due to air trapping.</li>\r\n<li><strong>C. Flattening of Diaphragm</strong>: Frequently observed in hyperinflated lungs.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Uniform ventilation perfusion matching</strong> does not occur in emphysema; instead, <strong>nonuniformity</strong> is typical due to structural damage.</li>\r\n<li>Recognizing these features is crucial for diagnosing and managing <strong>COPD</strong>, particularly emphysema.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 44,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\"><80%</span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\"><60%</span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\"><30%</span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\"><50%</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Reduction in FEV1 below what level leads to development of hypoxia in COPD ?</span></p>",
      "unique_key": "DT1295723",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295723,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Correct Answer</strong>: <strong>&lt;50%</strong> - Reduction in <strong>FEV1</strong> below this level is associated with the development of <strong>hypoxia</strong> in COPD.</li>\r\n</ul>\r\n<p><strong>Key Clinical Findings in COPD:</strong></p>\r\n<ol>\r\n<li><strong>Hyperinflation</strong>:\r\n<ul>\r\n<li>Results in a <strong>barrel-shaped chest</strong> and poor diaphragmatic function during respiration.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Use of Accessory Muscles</strong>:\r\n<ul>\r\n<li>Patients often adopt a <strong>tripod position</strong> to facilitate breathing, activating muscles like the <strong>sternocleidomastoid</strong>, <strong>scalene</strong>, and <strong>intercostal</strong></li>\r\n</ul>\r\n</li>\r\n<li><strong>Cyanosis</strong>:\r\n<ul>\r\n<li>More prominent in <strong>Chronic Bronchitis</strong> than in emphysema, leading to the terms <strong>\"blue bloaters\"</strong> for chronic bronchitis and <strong>\"pink puffers\"</strong> for emphysema patients.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Signs of Pulmonary Hypertension</strong>:\r\n<ul>\r\n<li>Severe pulmonary arterial hypertension can lead to <strong>cor pulmonale</strong> and right ventricular failure in patients with significant decreases in <strong>FEV1</strong> (&lt;25% of predicted) and chronic hypoxemia (<strong>Pao2</strong> &lt;55 mmHg).</li>\r\n<li><strong>Pao2</strong> typically remains near normal until <strong>FEV1</strong> decreases below <strong>50%</strong> of predicted.</li>\r\n</ul>\r\n</li>\r\n</ol>\r\n<p><strong>Why Not Other Options:</strong></p>\r\n<ul>\r\n<li><strong> &lt;80%</strong>: Generally does not indicate hypoxia.</li>\r\n<li><strong> &lt;60%</strong>: Still above the threshold for significant hypoxia.</li>\r\n<li><strong> &lt;30%</strong>: Hypoxia is likely to occur, but the critical threshold for clinical recognition is &lt;50%.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li>Hypoxia in COPD typically develops when <strong>FEV1</strong> drops below <strong>50%</strong> of the predicted value.</li>\r\n<li>Recognizing this threshold is essential for assessing the severity of COPD and implementing appropriate management strategies.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 54,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">Cyanosis</span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">Clubbing</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">Hoover sign</span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">Reduced diaphragmatic movement during respiration</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is not seen in COPD and its presence should initiate evaluation for other causes of Lung disease?</span></p>",
      "unique_key": "DT1295725",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295725,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Clubbing</strong>:\r\n<ul>\r\n<li><strong>Not a typical finding</strong> in COPD; indicates potential underlying lung pathology.</li>\r\n<li>Often associated with conditions like <strong>lung cancer</strong> or <strong>interstitial lung disease</strong>.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Common Symptoms of COPD</strong>:\r\n<ul>\r\n<li><strong>Cough</strong>: Persistent cough often productive of sputum.</li>\r\n<li><strong>Sputum production</strong>: Chronic sputum production is a hallmark.</li>\r\n<li><strong>Exertional dyspnea</strong>: Difficulty breathing during physical activities.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Physical Findings in COPD</strong>:\r\n<ul>\r\n<li><strong>Cyanosis</strong>:\r\n<ul>\r\n<li>Common in chronic bronchitis, indicating <strong>chronic hypoxia</strong>.</li>\r\n<li>Patients often referred to as \"blue bloaters.\"</li>\r\n</ul>\r\n</li>\r\n<li><strong>Hoover sign</strong>:\r\n<ul>\r\n<li>Characterized by <strong>paradoxical inward movement</strong> of the rib cage during inspiration.</li>\r\n<li>Reflects <strong>diaphragmatic dysfunction</strong> due to hyperinflation.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Reduced diaphragmatic movement</strong>:\r\n<ul>\r\n<li>Results from <strong>poor diaphragmatic execution</strong> during respiration.</li>\r\n<li>Sign of advanced disease where <strong>accessory muscles</strong></li>\r\n</ul>\r\n</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Why Not Other Options:</strong></p>\r\n<ul>\r\n<li><strong>A) Cyanosis</strong>:\r\n<ul>\r\n<li>Indicative of <strong>hypoxemia</strong>, commonly seen in chronic bronchitis patients.</li>\r\n</ul>\r\n</li>\r\n<li><strong>C) Hoover sign</strong>:\r\n<ul>\r\n<li>A significant clinical finding in <strong>advanced COPD</strong>, pointing to changes in diaphragmatic mechanics.</li>\r\n</ul>\r\n</li>\r\n<li><strong>D) Reduced diaphragmatic movement during respiration</strong>:\r\n<ul>\r\n<li>A typical feature in COPD due to <strong>hyperinflation</strong> affecting respiratory mechanics.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Clubbing is not associated with COPD</strong>; its presence necessitates investigation for other lung diseases.</li>\r\n<li>Common COPD symptoms include <strong>cough, sputum production,</strong> and <strong>dyspnea</strong>, while clubbing suggests a more serious underlying condition.</li>\r\n</ul>\r\n",
      "correct_choice_id": 62,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">Pi<sup>zz</sup></span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">Pi<sup>MZ</sup></span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">Pi<sup>MM</sup></span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">None of the above</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Presence of which genotype of antitrypsin gene is associated with highest risk of development of emphysema?</span></p>",
      "unique_key": "DT1295726",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295726,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Alpha-1 Antitrypsin (&alpha;1AT) Deficiency</strong>:\r\n<ul>\r\n<li><strong>Genotype Risk Hierarchy</strong>:\r\n<ul>\r\n<li><strong>Pizz</strong>: Highest risk for developing emphysema due to severe deficiency.</li>\r\n<li><strong>PiMZ</strong>: Intermediate risk; may develop emphysema but less severe than Pizz.</li>\r\n<li><strong>PiMM</strong>: Normal genotype with <strong>minimal risk</strong> for emphysema.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Characteristics of Pizz Genotype</strong>:\r\n<ul>\r\n<li>Individuals with two Z alleles (PiZZ) have the <strong>most severe deficiency</strong>.</li>\r\n<li>Development of <strong>early emphysema</strong> is common in these individuals.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Additional Risk Factors</strong>:\r\n<ul>\r\n<li><strong>Smoking</strong>: Particularly detrimental; a dose-dependent relationship exists.</li>\r\n<li><strong>Respiratory infections</strong>: Contribute significantly to disease exacerbations.</li>\r\n<li><strong>Occupational exposure</strong>: Coal dust and other harmful substances increase risk.</li>\r\n<li><strong>Biomass combustion</strong>: Exposure to smoke from burning biomass fuels is another factor.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Treatment</strong>:\r\n<ul>\r\n<li><strong>&alpha;1AT Augmentation Therapy</strong>:\r\n<ul>\r\n<li>Available for those with severe deficiency.</li>\r\n<li>Administered via weekly IV infusion, specifically for patients with serum &alpha;1AT levels &lt;11 &mu;M (~50 mg/dL).</li>\r\n<li>Not recommended for those with normal pulmonary function despite deficiency.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Why Not Other Options:</strong></p>\r\n<ul>\r\n<li><strong>B) PiMZ</strong>:\r\n<ul>\r\n<li>Carries a risk, but significantly lower than Pizz; not the highest risk genotype.</li>\r\n</ul>\r\n</li>\r\n<li><strong>C) PiMM</strong>:\r\n<ul>\r\n<li>Represents normal &alpha;1AT levels; hence, the risk of emphysema is minimal.</li>\r\n</ul>\r\n</li>\r\n<li><strong>D) None of the above</strong>:\r\n<ul>\r\n<li>Incorrect as Pizz is indeed associated with the highest risk of emphysema.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li>The <strong>Pizz genotype</strong> signifies the highest risk of emphysema due to severe &alpha;1AT deficiency.</li>\r\n<li>Other contributing factors include <strong>smoking, respiratory infections</strong>, and <strong>occupational exposures</strong>, all increasing the likelihood of developing emphysema in susceptible individuals.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 71,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">GOLD staging </span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">Simplified disease activity index</span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">Clinical disease activity Index</span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">BODE index</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is a comprehensive Index is used for prognostication of COPD patients?</span></p>",
      "unique_key": "DT1295727",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295727,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>BODE Index</strong>:\r\n<ul>\r\n<li>A comprehensive <strong>multifactorial prognostic index</strong> specifically for COPD patients.</li>\r\n<li>Components of the BODE index:\r\n<ul>\r\n<li><strong>B</strong>: BMI (Body Mass Index)</li>\r\n<li><strong>O</strong>: Airway obstruction (measured by FEV1)</li>\r\n<li><strong>D</strong>: Dyspnea (breathlessness severity)</li>\r\n<li><strong>E</strong>: Exercise performance (often assessed by the 6-minute walk test).</li>\r\n</ul>\r\n</li>\r\n<li><strong>Comparison with Other Options</strong>:\r\n<ul>\r\n<li><strong>GOLD Staging</strong>: Focuses solely on the <strong>severity of airflow obstruction</strong>, not a comprehensive prognostic tool.</li>\r\n<li><strong>Simplified Disease Activity Index &amp; Clinical Disease Activity Index</strong>: Primarily measures <strong>disease activity in rheumatoid arthritis</strong>, not COPD.</li>\r\n<li><strong>ABG (Arterial Blood Gas)</strong>: Useful for assessing <strong>hypoxia and acidosis</strong> but does not provide a comprehensive prognostic index like BODE.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Why Not Other Options:</strong></p>\r\n<ul>\r\n<li><strong>A) GOLD Staging</strong>:\r\n<ul>\r\n<li>It quantifies airflow obstruction severity but lacks comprehensive prognostic capabilities.</li>\r\n</ul>\r\n</li>\r\n<li><strong>B) Simplified Disease Activity Index</strong>:\r\n<ul>\r\n<li>Specific to rheumatoid arthritis; not applicable for COPD prognosis.</li>\r\n</ul>\r\n</li>\r\n<li><strong>C) Clinical Disease Activity Index</strong>:\r\n<ul>\r\n<li>Also specific to rheumatoid arthritis; irrelevant for COPD patients.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li>The <strong>BODE index</strong> serves as a comprehensive prognostic tool for assessing COPD severity and outcomes.</li>\r\n<li>Other indices, like <strong>GOLD staging</strong>, focus on airflow obstruction but do not encompass the multifactorial nature of COPD prognosis.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 84,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">Surgical lung biopsy</span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">Bronchoscopic biopsy</span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">HRCT chest</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">Spirometry (pulmonary function test)</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Definite diagnosis of emphysema is done by?</span></p>",
      "unique_key": "DT1295728",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295728,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>HRCT Chest</strong>:\r\n<ul>\r\n<li><strong>High-Resolution Computed Tomography (HRCT)</strong> is the <strong>definitive diagnostic tool</strong> for emphysema.</li>\r\n<li>It effectively identifies:\r\n<ul>\r\n<li><strong>Emphysema presence</strong> and severity.</li>\r\n<li><strong>Diseases affecting medium and small airways</strong>.</li>\r\n<li><strong>Ruling out other conditions</strong> like lung carcinoma and coexisting bronchiectasis.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Comparison with Other Options</strong>:\r\n<ul>\r\n<li><strong>Surgical Lung Biopsy</strong>:\r\n<ul>\r\n<li>Not routinely performed for COPD diagnosis; invasive and not necessary.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Bronchoscopic Biopsy</strong>:\r\n<ul>\r\n<li>Limited use in diagnosing emphysema; primarily for obtaining samples in suspected malignancies or infections.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Spirometry</strong>:\r\n<ul>\r\n<li>Useful for assessing lung function and airflow obstruction but <strong>does not definitively diagnose emphysema</strong>.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Why Not Other Options:</strong></p>\r\n<ul>\r\n<li><strong>A) Surgical Lung Biopsy</strong>:\r\n<ul>\r\n<li>Invasive procedure with limited utility in confirming emphysema; primarily used for lung cancers or interstitial lung disease.</li>\r\n</ul>\r\n</li>\r\n<li><strong>B) Bronchoscopic Biopsy</strong>:\r\n<ul>\r\n<li>Mainly indicates conditions like infections or malignancies; not a direct diagnostic method for emphysema.</li>\r\n</ul>\r\n</li>\r\n<li><strong>D) Spirometry (Pulmonary Function Test)</strong>:\r\n<ul>\r\n<li>Assesses lung function and airflow limitation but cannot confirm the presence of emphysema specifically.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li>The <strong>HRCT chest</strong> is essential for the <strong>definitive diagnosis</strong> of emphysema and to assess the extent of airway disease.</li>\r\n<li><strong>Biopsy techniques</strong> like surgical or bronchoscopic are not appropriate for diagnosing emphysema directly.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 93,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">Inhalational corticosteroids</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">Lung volume reduction surgery</span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">Supplemental oxygen</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">Smoking cessation</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">All of the following interventions in Emphysema are known to reduce Mortality except?</span></p>",
      "unique_key": "DT1295729",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295729,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Inhalational Corticosteroids</strong>:\r\n<ul>\r\n<li><strong>Do not reduce mortality</strong> in emphysema; primarily used for managing inflammation and exacerbations.</li>\r\n<li><strong>Role</strong>: Help improve symptoms and lung function but lack evidence for mortality benefit.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Interventions Known to Reduce Mortality</strong>:\r\n<ul>\r\n<li><strong>Smoking Cessation</strong>:\r\n<ul>\r\n<li>The most effective intervention; halting smoking significantly slows disease progression and reduces mortality.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Lung Volume Reduction Surgery (LVRS)</strong>:\r\n<ul>\r\n<li>Effective for selected patients with localized emphysema; improves quality of life and survival.</li>\r\n<li><strong>Indication</strong>: Best for patients with upper lobe-predominant disease and poor exercise capacity.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Supplemental Oxygen</strong>:\r\n<ul>\r\n<li>Increases survival in patients with hypoxemia; crucial for managing chronic respiratory failure.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Why Not Other Options:</strong></p>\r\n<ul>\r\n<li><strong>B) Lung Volume Reduction Surgery</strong>:\r\n<ul>\r\n<li>Proven to enhance survival and quality of life in appropriately selected patients with localized emphysema.</li>\r\n</ul>\r\n</li>\r\n<li><strong>C) Supplemental Oxygen</strong>:\r\n<ul>\r\n<li>Extensively documented to improve survival rates in COPD patients with severe hypoxemia.</li>\r\n</ul>\r\n</li>\r\n<li><strong>D) Smoking Cessation</strong>:\r\n<ul>\r\n<li>Widely recognized as the most effective way to improve longevity in COPD patients, reducing both morbidity and mortality.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Inhalational corticosteroids</strong> do not contribute to mortality reduction in emphysema, unlike smoking cessation, LVRS, and supplemental oxygen.</li>\r\n<li><strong>Effective management</strong> of emphysema focuses on interventions that significantly impact survival and quality of life.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 101,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">Inhalational Bronchodilators</span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">Oral corticosteroids</span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">Supplemental oxygen therapy</span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">Phosphodiesterase inhibitor</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is considered primary treatment for symptomatic management of COPD?</span></p>",
      "unique_key": "DT1295730",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295730,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Inhalational Bronchodilators</strong>:\r\n<ul>\r\n<li><strong>Cornerstone of symptomatic treatment</strong> for COPD.</li>\r\n<li><strong>Types</strong>: Include Long-Acting Beta-Agonists (LABAs) and Long-Acting Muscarinic Antagonists (LAMAs).</li>\r\n<li><strong>Mechanism</strong>: Relax airway muscles, leading to improved airflow and reduced symptoms.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Treatment Algorithm for COPD Management</strong>:\r\n<ul>\r\n<li><strong>Step 1</strong>: Start with LABA or LAMA for initial therapy.</li>\r\n<li><strong>Step 2</strong>: Combine LABA with LAMA or LABA with inhalational corticosteroids for patients needing further symptom control.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Drugs Used</strong>:\r\n<ul>\r\n<li><strong>LAMA Examples</strong>: Aclidinium, Glycopyrrolate, Tiotropium, Umeclidinium.\r\n<ul>\r\n<li><strong>Benefits</strong>: Improve symptoms and reduce exacerbations.</li>\r\n</ul>\r\n</li>\r\n<li><strong>LABA Examples</strong>: Formoterol, Indacaterol, Salmeterol.\r\n<ul>\r\n<li><strong>Side Effects</strong>: Tremor and tachycardia.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Inhaled Corticosteroids</strong>: Used for reducing exacerbations, offering little symptomatic benefit.</li>\r\n<li><strong>Oral Corticosteroids</strong>: Reserved for acute exacerbations, not for routine management.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Why Not Other Options:</strong></p>\r\n<ul>\r\n<li><strong>B) Oral Corticosteroids</strong>:\r\n<ul>\r\n<li>Used primarily during acute exacerbations, not for routine symptomatic management in COPD.</li>\r\n</ul>\r\n</li>\r\n<li><strong>C) Supplemental Oxygen Therapy</strong>:\r\n<ul>\r\n<li>Essential for managing hypoxemia but does not directly alleviate COPD symptoms; not considered a primary treatment.</li>\r\n</ul>\r\n</li>\r\n<li><strong>D) Phosphodiesterase Inhibitor</strong>:\r\n<ul>\r\n<li>Used as an adjunct therapy in specific cases; not the primary treatment for symptomatic management in COPD.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Inhalational bronchodilators</strong> are the primary treatment for symptomatic relief in COPD, significantly improving airflow and reducing symptoms.</li>\r\n<li><strong>Effective management</strong> requires understanding the stepwise approach, emphasizing bronchodilators as first-line therapy.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 111,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">Theophylline</span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">Roflumilast</span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">Vilanterol</span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">Both A and B</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following drugs used for management of  COPD are phosphodiesterase inhibitor?</span></p>",
      "unique_key": "DT1295731",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295731,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Theophylline</strong>:\r\n<ul>\r\n<li>A <strong>nonspecific phosphodiesterase inhibitor</strong> that leads to <strong>bronchodilation</strong>.</li>\r\n<li>Mechanism: Inhibits the breakdown of cyclic AMP, resulting in relaxation of airway smooth muscle.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Roflumilast</strong>:\r\n<ul>\r\n<li>A <strong>selective phosphodiesterase-4 (PDE4) inhibitor</strong>.</li>\r\n<li><strong>Indication</strong>: Reduces exacerbation frequency in severe COPD and chronic bronchitis.</li>\r\n<li><strong>Mechanism</strong>: Decreases inflammation in the airways.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Other Relevant Drugs</strong>:\r\n<ul>\r\n<li><strong>Azithromycin</strong>: Exhibits <strong>immunomodulatory properties</strong>; shown to reduce exacerbation frequency in COPD patients with a history of exacerbations, but not a phosphodiesterase inhibitor.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Why Not Other Options:</strong></p>\r\n<ul>\r\n<li><strong>A) Theophylline</strong>:\r\n<ul>\r\n<li>Although it is a phosphodiesterase inhibitor, it is not specific and primarily acts as a bronchodilator.</li>\r\n</ul>\r\n</li>\r\n<li><strong>B) Roflumilast</strong>:\r\n<ul>\r\n<li>It is indeed a phosphodiesterase inhibitor, but not the nonspecific type like theophylline. It acts selectively on PDE4.</li>\r\n</ul>\r\n</li>\r\n<li><strong>C) Vilanterol</strong>:\r\n<ul>\r\n<li>A long-acting beta-agonist (LABA), not a phosphodiesterase inhibitor; it primarily works through adrenergic pathways to induce bronchodilation.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Both Theophylline and Roflumilast</strong> are phosphodiesterase inhibitors used in COPD management, although they differ in specificity and mechanism of action.</li>\r\n<li>Understanding the role of <strong>phosphodiesterase inhibitors</strong> is essential for effective COPD treatment strategies.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 124,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14,
      "choices": [
        {
          "id": 131,
          "text": "<p><span style=\"font-size:12.0pt;\">All diagnosed cases of COPD with dyspnoea.</span></p>"
        },
        {
          "id": 132,
          "text": "<p><span style=\"font-size:12.0pt;\">COPD patients with resting SPO2<95%</span></p>"
        },
        {
          "id": 133,
          "text": "<p><span style=\"font-size:12.0pt;\">COPD patients with resting SPO2<92%</span></p>"
        },
        {
          "id": 134,
          "text": "<p><span style=\"font-size:12.0pt;\">COPD patients with resting SPO2<88%</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Supplemental oxygen therapy has shown to reduce mortality in COPD. What is the indication for starting Oxygen Therapy in COPD patients?</span></p>",
      "unique_key": "DT1295732",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295732,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Supplemental Oxygen Therapy</strong>:\r\n<ul>\r\n<li>The only pharmacologic treatment proven to <strong>significantly reduce mortality</strong> in COPD patients.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Indication for Oxygen Therapy</strong>:\r\n<ul>\r\n<li>Initiated in patients with <strong>resting hypoxemia</strong>, specifically:\r\n<ul>\r\n<li><strong>Resting SpO2 &le; 88%</strong> for any patient.</li>\r\n<li><strong>Resting SpO2 &le; 89%</strong> if accompanied by signs of:\r\n<ul>\r\n<li><strong>Pulmonary arterial hypertension</strong></li>\r\n<li><strong>Right heart failure</strong></li>\r\n<li><strong>Erythrocytosis</strong></li>\r\n</ul>\r\n</li>\r\n<li><strong>Objective</strong>:\r\n<ul>\r\n<li>Maintain adequate oxygenation and prevent complications associated with chronic hypoxemia.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Why Not Other Options:</strong></p>\r\n<ul>\r\n<li><strong>A) All diagnosed cases of COPD with dyspnea</strong>:\r\n<ul>\r\n<li>Not all patients require oxygen; dyspnea does not automatically indicate the need for oxygen therapy without hypoxemia.</li>\r\n</ul>\r\n</li>\r\n<li><strong>B) COPD patients with resting SpO2 &lt; 95%</strong>:\r\n<ul>\r\n<li>While low, this level does not necessarily indicate a need for supplemental oxygen therapy as it does not meet the criteria for significant hypoxemia.</li>\r\n</ul>\r\n</li>\r\n<li><strong>C) COPD patients with resting SpO2 &lt; 92%</strong>:\r\n<ul>\r\n<li>Although lower than normal, it is still above the threshold indicating the need for oxygen therapy, which is &lt; 88%.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Oxygen therapy is indicated</strong> for COPD patients with resting SpO2 &lt; 88%, significantly improving survival rates.</li>\r\n<li>Proper <strong>assessment of oxygen saturation</strong> is critical for managing hypoxemia in COPD effectively.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 134,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15,
      "choices": [
        {
          "id": 141,
          "text": "<p><span style=\"font-size:12.0pt;\">HRCT chest</span></p>"
        },
        {
          "id": 142,
          "text": "<p><span style=\"font-size:12.0pt;\">Chest X-ray view</span></p>"
        },
        {
          "id": 143,
          "text": "<p><span style=\"font-size:12.0pt;\">ABG</span></p>"
        },
        {
          "id": 144,
          "text": "<p><span style=\"font-size:12.0pt;\">Total leukocyte counts</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A diagnosed case of Chronic obstructive pulmonary disease repots worsening of dyspnoea, productive cough with increased purulence of cough. He is brought to medical emergency in altered sensorium. Possible Diagnosis of acute exacerbation of COPD is kept. Which of the following should be done next for confirmation of diagnosis and to establish the severity of exacerbation of COPD?</span></p>",
      "unique_key": "DT1295733",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295733,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Acute Exacerbation of COPD</strong>:\r\n<ul>\r\n<li>Characterized by worsening respiratory symptoms, including:\r\n<ul>\r\n<li><strong>Increased dyspnea</strong></li>\r\n<li><strong>Productive cough with purulent sputum</strong></li>\r\n<li><strong>Altered sensorium</strong> indicating possible severe respiratory distress.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Next Steps for Confirmation</strong>:\r\n<ul>\r\n<li><strong>Arterial Blood Gas (ABG) Analysis</strong>:\r\n<ul>\r\n<li>Essential for assessing <strong>oxygenation and ventilation status</strong>.</li>\r\n<li>Particularly important in patients with:\r\n<ul>\r\n<li><strong>Altered sensorium</strong></li>\r\n<li><strong>History of hypercarbia</strong>.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Hypercarbia</strong> (PaCO2 &gt; 45 mmHg) has critical management implications.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Other Investigations</strong>:\r\n<ul>\r\n<li><strong>HRCT chest and chest X-ray</strong> may help in evaluating lung pathology but are not definitive for diagnosing exacerbation.</li>\r\n<li><strong>Total leukocyte counts</strong> can indicate infection but do not establish severity or confirm acute exacerbation.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p>Evaluation of exacerbation:</p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20250109eecd9e79-4d4b-426b-a567-2baa22f010a7.jpg\"><p><strong>Why Not Other Options:</strong></p>\r\n<ul>\r\n<li><strong>A) HRCT chest</strong>:\r\n<ul>\r\n<li>Not typically used in acute exacerbations; more suited for chronic evaluation and specific lung pathology.</li>\r\n</ul>\r\n</li>\r\n<li><strong>B) Chest X-ray view</strong>:\r\n<ul>\r\n<li>Useful for ruling out complications like pneumonia or pneumothorax but does not assess gas exchange or severity of exacerbation.</li>\r\n</ul>\r\n</li>\r\n<li><strong>D) Total leukocyte counts</strong>:\r\n<ul>\r\n<li>While it may indicate infection, it does not provide direct information about respiratory failure or the severity of the exacerbation.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>ABG is crucial for confirming acute exacerbation of COPD</strong> and assessing respiratory failure severity.</li>\r\n<li>Prompt recognition and management are essential for optimizing treatment and improving patient outcomes.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 143,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}